[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chengdu University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":228},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,70,92,113,132,158,183,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100624056","microwave-ablation-for-treatment-of-vascular-malformations-efficacy-and-safety-100624056",false,"NCT07404670","Microwave Ablation for Treatment of Vascular Malformations: Efficacy and Safety","A Multicenter, Prospective Study to Analyze the Efficacy and Safety of Microwave Ablation for the Treatment of Vascular Malformations","Inclusion Criteria:\n\n1. Patients with clinically diagnosed vascular malformations (venous malformations (VM) or arteriovenous malformations (AVM)) confirmed by MRI or ultrasound.\n2. Presence of symptomatic lesions (pain, swelling, functional impairment, or ulceration) that require treatment.\n3. Lesions that are amenable to microwave ablation based on preoperative clinical and imaging assessment.\n4. Ability to provide informed consent or parental consent for minors (if applicable).\n\nExclusion Criteria:\n\n1. Capillary malformations or congenital arteriovenous fistula.\n2. Lesions that are too close to critical structures (e.g., major blood vessels or nerves) and cannot be safely treated.\n3. Pregnancy or breastfeeding.\n4. Severe coagulopathy or significant bleeding disorders.\n5. Active infection at the treatment site.\n6. Patients with severe uncontrolled systemic disease that could interfere with treatment or recovery.\n7. Recent treatments (e.g., surgery, sclerotherapy, embolization) for the same lesion within the last 6 months.","ALL",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"NA","This clinical trial aims to assess the safety and efficacy of microwave ablation in treating vascular malformations, including both venous malformations (VM) and arteriovenous malformations (AVM). Vascular malformations are abnormal clusters of blood vessels that can cause pain, swelling, and functional impairment, significantly affecting a patient's quality of life. Microwave ablation is a minimally invasive treatment that uses heat to shrink abnormal vessels, but its effectiveness and safety for these conditions need further investigation.\n\nThe trial will enroll 150 patients (100 with venous malformations and 50 with arteriovenous malformations), all of whom will undergo a single session of microwave ablation. Ultrasound guidance will be used during the procedure to precisely target the lesions, while MRI will be used for both preoperative and postoperative evaluations to assess lesion size and track changes over time.\n\nThe primary goals of the study are to determine whether microwave ablation can reduce lesion size and improve symptoms such as pain and swelling. Additionally, the study will monitor adverse events to evaluate the safety of the procedure, including any potential complications like infection, bleeding, or nerve injury.\n\nPatients will be followed for 12 months, with MRI scans taken at 1 month, 3 months, 6 months, and 12 months after the procedure to evaluate lesion shrinkage and monitor for any recurrence. Clinical symptoms will also be assessed at these time points to track improvement.\n\nThis study could provide important data on the safety and efficacy of microwave ablation, potentially offering a less invasive treatment option for patients with vascular malformations.",[25,26,27,28],"Venous Malformations","Arteriovenous Malformations","Microwave Ablation","Vascular Malformations",[27,28,25,26,30],"Minimally Invasive Treatment","NOT_YET_RECRUITING","2026-02-05",{"date":34,"type":35},"2026-02-11","ACTUAL",{"date":37,"type":19},"2026-03-01",{"date":39,"type":19},"2028-03-01",{"name":41,"class":42},"Chengdu University of Traditional Chinese Medicine","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100611338","efficacy-and-safety-of-endovenous-ablation-for-relief-of-knee-pain-in-elderly-patients-with-lower-extremity-varicose-veins-a-prospective-observational-study-100611338","NCT07239284","Efficacy and Safety of Endovenous Ablation for Relief of Knee Pain in Elderly Patients With Lower Extremity Varicose Veins: A Prospective Observational Study","EVA-Knee-Elder","Inclusion Criteria:\n\nAdults aged ≥80 years. Clinical diagnosis of lower limb varicose veins with documented venous reflux on duplex ultrasound (CEAP C2-C4).\n\nPresence of knee pain lasting ≥4 weeks prior to enrollment, confirmed by patient-reported VAS\u002FNRS ≥3 at baseline.\n\nPlanned to undergo standard endovenous treatment (radiofrequency ablation, endovenous laser ablation, or equivalent).\n\nAbility to provide informed consent and complete study questionnaires.\n\nExclusion Criteria:\n\nPrior surgery or endovenous ablation for varicose veins in the same limb. History of inflammatory arthritis (e.g., rheumatoid arthritis, gout) or other systemic rheumatologic disease.\n\nRecent acute knee injury (ligament, meniscus, fracture) within 6 months. Prior knee replacement or major knee surgery. Recent intra-articular injection or arthroscopy (\\\u003C3 months). Known deep vein thrombosis or history of pulmonary embolism within the past 6 months.\n\nSevere peripheral arterial disease (ABI \\\u003C0.8). Pregnancy or breastfeeding. Inability to comply with follow-up schedule or complete questionnaires.","80 Years",{"count":52,"type":19},50,"6 Months","OBSERVATIONAL","Lower extremity varicose veins (LEVV) are common among elderly patients and can cause leg heaviness, pain, and swelling. In some older adults, venous congestion may contribute to knee or peri-knee pain, which is often misattributed to degenerative joint disease alone. Evidence on whether varicose vein treatment can relieve knee pain in very elderly patients (aged 80 years or older) is limited.\n\nThis prospective cohort study aims to evaluate the effectiveness and safety of endovenous ablation (EVA) for improving knee pain in elderly patients with symptomatic varicose veins. The study will include participants aged 80 years or older who present with both lower extremity varicose veins and knee joint pain. Eligible patients will undergo endovenous thermal ablation (radiofrequency or endovenous laser ablation) as the primary intervention.\n\nParticipants will be assessed at baseline, 1 month, 3 months, 6 months, and 12 months after treatment. The primary outcome is the change in knee pain intensity measured by the Visual Analog Scale (VAS) from baseline to 6 months. Secondary outcomes include changes in knee joint function (assessed by the Western Ontario and McMaster Universities Osteoarthritis Index \\[WOMAC\\] or Knee Injury and Osteoarthritis Outcome Score \\[KOOS\\]), venous clinical severity score (VCSS), limb heaviness, quality of life (assessed by EQ-5D), and procedure-related complications.\n\nSafety will be evaluated by recording peri-procedural adverse events, including deep vein thrombosis, skin burns, nerve injury, and postoperative infection. The study will also analyze whether preexisting osteoarthritis, venous reflux severity, or body mass index (BMI) affect the magnitude of pain improvement.\n\nThe hypothesis is that endovenous ablation improves knee pain in elderly patients by reducing venous congestion around the knee and improving venous return. This study will help clarify whether treating varicose veins can provide additional benefits for knee pain and mobility in patients aged 80 years and older.",[57,58,59,60,61],"Varicose Veins of Lower Limb","Chronic Venous Insufficiency, CVI","Knee Pain","Knee Osteoarthritis","Elderly Patients","2025-11-16",{"date":64,"type":35},"2025-11-20",{"date":66,"type":19},"2025-12-10",{"date":68,"type":19},"2027-07-10",{"name":41,"class":42},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":77,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100610902","risks-and-benefits-of-radiofrequency-ablation-for-chronic-venous-insufficiency-ceap-c3-c6-in-patients-aged-80-and-over-100610902","NCT07233616","Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over","Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over: A Prospective Single-Arm Cohort Study","Inclusion Criteria:\n\n1. Age: Aged 80 years or older.\n2. Clinical Diagnosis: Symptomatic chronic venous insufficiency of the lower extremity, with the highest clinical class (CEAP classification) being one of the following:\n\n   * C3: Venous edema\n   * C4a: Pigmentation or eczema\n   * C4b: Lipodermatosclerosis or atrophie blanche\n   * C5: Healed venous ulcer\n   * C6: Active venous ulcer\n3. Confirmed Reflux: Color duplex ultrasound examination confirming reflux (reflux time \\> 0.5 seconds) in the great saphenous vein (GSV) and\u002For small saphenous vein (SSV) of the target limb.\n4. Informed Consent: The patient or their legally authorized representative is able to understand and voluntarily provides written informed consent.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria will be excluded from the study:\n\n  1. Mobility: Non-ambulatory or bedridden.\n  2. Thrombosis: Presence of acute superficial thrombophlebitis of the target vein, or deep vein thrombosis (DVT) in the target limb.\n  3. Arterial Disease: Significant peripheral arterial disease, defined as an ankle-brachial index (ABI) \\\u003C 0.8 in the target limb.\n  4. Coagulopathy: Uncorrectable coagulation disorder.\n  5. Allergy: Known severe allergy to local anesthetics (e.g., lidocaine) or relevant device materials.\n  6. Cognition \\& Compliance: Severe cognitive impairment or psychiatric illness that, in the investigator's judgment, precludes adequate understanding and cooperation for the study procedures and follow-up.\n  7. Life Expectancy: Life expectancy of less than 1 year due to other comorbid conditions (e.g., terminal malignancy).\n  8. General Unsuitability: Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.",{"count":52,"type":19},"The prevalence of severe chronic venous insufficiency (CVI) is significant in the growing octogenarian population. While radiofrequency ablation (RFA) is a standard minimally invasive treatment, robust data on its outcomes and safety profiles specifically in patients aged 80 years and older remain scarce. This study aims to evaluate the risks and benefits of RFA in this specific, high-risk demographic.This prospective, single-arm, single-center cohort study will enroll 50 patients (initial target sample size) aged ≥80 years with CVI classified as CEAP C3 to C6 and with confirmed great or small saphenous vein reflux. All participants will undergo endovenous RFA under tumescent local anesthesia. The primary outcomes are: 1) the great\u002Fsmall saphenous vein occlusion rate at 6 months, assessed by duplex ultrasonography, and 2) the change in disease-specific quality of life from baseline to 6 months, measured by the Aberdeen Varicose Vein Questionnaire (AVVQ). Secondary outcomes include occlusion rates at 1 and 3 months; complication rates (e.g., deep vein thrombosis, skin burns, paresthesia) within 30 days; and changes in the Venous Clinical Severity Score (VCSS) and the 12-Item Short Form Health Survey (SF-12) at predefined intervals over 6 months.This study is designed to demonstrate a high technical success rate (occlusion rate \\>95% at 6 months) and a statistically significant improvement in AVVQ and VCSS scores at 6 months post-procedure. The collected data will provide a detailed profile of complication rates, characterizing the safety of RFA in this very elderly cohort.This study will provide crucial, prospective evidence regarding the efficacy and safety of RFA for treating CVI in octogenarians. The findings are expected to guide clinical decision-making and inform treatment guidelines for this vulnerable and expanding patient population.",[58,80,81,82],"Radiofrequency Ablation","Octogenarians(Aged 80 and Over)","Cohort Study","RECRUITING",{"date":85,"type":35},"2025-11-18",{"date":87,"type":35},"2025-10-01",{"date":89,"type":19},"2026-09-01",{"name":41,"class":42},1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100608987","effect-of-oral-antiplatelet-or-anticoagulant-drugs-on-postoperative-bleeding-risk-and-venous-closure-rate-in-patients-with-lower-extremity-varicose-veins-after-radiofrequency-ablation-100608987","NCT07208695","Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","Inclusion Criteria:\n\n* Aged 18 years or older, with a confirmed diagnosis of primary lower extremity varicose veins (CEAP classification C2-C6) based on clinical examination and duplex ultrasound.\n* Underwent endovenous radiofrequency ablation (RFA) of the great saphenous vein as the primary intervention.\n* Postoperatively, either: (a) continuously uses standard-dose oral antiplatelet drugs (e.g., aspirin 100mg\u002Fday, clopidogrel 75mg\u002Fday) or oral anticoagulant drugs (e.g., warfarin with INR maintained at 2.0-3.0, direct oral anticoagulants at standard therapeutic doses) as per clinical routine, or (b) does not use any antithrombotic drugs.\n* Able to understand and comply with the follow-up schedule (including 30-day bleeding assessment and 6-month duplex ultrasound examination) and provide informed consent.\n\nExclusion Criteria:\n\n* Presence of secondary varicose veins caused by deep vein thrombosis, venous malformation, or other vascular disorders.\n* History of coagulation disorders (e.g., hemophilia, thrombocytopenia with platelet count \\\u003C100×10⁹\u002FL) or use of other antithrombotic agents (e.g., low-molecular-weight heparin, glycoprotein IIb\u002FIIIa inhibitors) postoperatively.\n* Major bleeding events (e.g., gastrointestinal bleeding, intracranial hemorrhage) within 3 months prior to RFA.\n* Severe hepatic insufficiency (Child-Pugh class C), renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), or other life-threatening systemic diseases.\n* Unable to complete follow-up due to mental disorders, mobility limitations, or other reasons, or refusal to sign the informed consent form.","18 Years",{"count":100,"type":19},40,"This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation. Its main objectives are to determine the impact of these medications on postoperative 30-day bleeding risk and postoperative 3-month venous closure rate in this patient population. Researchers will compare three groups-patients receiving oral antiplatelet drugs, those receiving oral anticoagulant drugs, and those not receiving either type of drug-to identify differences in the two key outcomes. Participants will complete baseline data collection (including medical history, medication use, and lower extremity venous assessment) before or shortly after radiofrequency ablation, undergo 30-day postoperative follow-up to evaluate bleeding events (such as minor bleeding or major bleeding requiring medical intervention), receive venous ultrasound at 3 months postoperatively to measure venous closure rate, and report any medication changes or adverse events during the follow-up period.",[103,104,105,80],"Oral Antiplatele","Anticoagulant Drugs","Lower Extremity Varicose Veins","2025-09-28",{"date":108,"type":35},"2025-10-06",{"date":87,"type":19},{"date":111,"type":19},"2026-06-01",{"name":41,"class":42},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":50,"enrollmentInfo":121,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100605499","knee-pain-relief-after-endovenous-treatment-for-lower-limb-varicose-veins-a-prospective-observational-study-100605499","NCT07163312","Knee Pain Relief After Endovenous Treatment for Lower Limb Varicose Veins: A Prospective Observational Study","Prospective Observational Cohort Study of Knee Pain and Function After Endovenous Treatment for Lower Limb Varicose Veins","VV-KNEE","Inclusion Criteria:\n\nAdults aged ≥18 years. Clinical diagnosis of lower limb varicose veins with documented venous reflux on duplex ultrasound (CEAP C2-C4).\n\nPresence of knee pain lasting ≥4 weeks prior to enrollment, confirmed by patient-reported VAS\u002FNRS ≥3 at baseline.\n\nPlanned to undergo standard endovenous treatment (radiofrequency ablation, endovenous laser ablation, or equivalent).\n\nAbility to provide informed consent and complete study questionnaires.\n\nExclusion Criteria:\n\nPrior surgery or endovenous ablation for varicose veins in the same limb. History of inflammatory arthritis (e.g., rheumatoid arthritis, gout) or other systemic rheumatologic disease.\n\nRecent acute knee injury (ligament, meniscus, fracture) within 6 months. Prior knee replacement or major knee surgery. Recent intra-articular injection or arthroscopy (\\\u003C3 months). Known deep vein thrombosis or history of pulmonary embolism within the past 6 months.\n\nSevere peripheral arterial disease (ABI \\\u003C0.8). Pregnancy or breastfeeding. Inability to comply with follow-up schedule or complete questionnaires.",{"count":52,"type":19},"This study will observe patients with lower limb varicose veins who also have knee pain. Many patients with varicose veins experience swelling, heaviness, or aching in the legs, and some also report pain in or around the knee. Previous studies suggest that venous reflux and poor circulation may increase discomfort in the knee, especially when knee osteoarthritis is present.\n\nThe purpose of this study is to evaluate whether treatment of varicose veins with standard endovenous procedures can improve knee pain and function. Participants will undergo standard vein treatment as part of their clinical care. We will follow them for changes in knee pain, quality of life, and leg symptoms over time.\n\nThis study does not assign patients to experimental interventions. Instead, it collects information before and after treatment to better understand the relationship between varicose veins and knee pain relief. Findings from this study may help doctors identify which patients are most likely to benefit from venous treatment in terms of both leg and knee symptoms.",[57,58,124,60],"Knee Pain Chronic","2025-09-01",{"date":127,"type":35},"2025-09-09",{"date":87,"type":19},{"date":130,"type":19},"2026-11-01",{"name":41,"class":42},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":50,"enrollmentInfo":139,"targetDuration":4,"studyType":20,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":91},"100596501","clinical-outcomes-safety-and-cost-effectiveness-analysis-of-two-catheters-xianrui-da-and-medtronic-in-radiofrequency-ablation-for-varicose-veins-100596501","NCT07046286","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui Da and Medtronic) in Radiofrequency Ablation for Varicose Veins","Clinical Outcomes, Safety, and Cost-Effectiveness Analysis of Two Catheters (Xianrui and Medtronic) in Radiofrequency Ablation for Varicose Veins","Inclusion Criteria:\n\n1. Age between 18 and 80 years old.\n2. Clinically diagnosed with primary lower extremity varicose veins, with CEAP grade C2 - C5, and requiring treatment of the great saphenous vein segment.\n3. Doppler ultrasound confirms that the reflux time of the saphenofemoral vein valve is \\> 1.0 second.\n4. Doppler ultrasound confirms that the diameter of the great saphenous vein in the supine position is \\> 3mm and \\\u003C 12mm.\n5. Only one limb of each patient is included in the study.\n6. The patient signs the informed consent form and is willing to cooperate with the examinations and follow - ups specified in the protocol.\n\nExclusion Criteria:\n\n1. Thrombosis in the great saphenous vein, or combined with deep vein thrombosis, or a history of deep vein thrombosis or pulmonary embolism.\n2. Recurrent varicose veins after previous treatment.\n3. Severe tortuosity of the great saphenous vein, with the expectation that the catheter cannot pass through.\n4. Severe lower extremity ischemia (CLI).\n5. Known allergy to drugs or device materials involved in the study.\n6. History of cardiac pacemaker or defibrillator implantation.\n7. Pregnant or breastfeeding women.\n8. Currently participating in other drug or device studies.\n9. Deemed unsuitable for endovenous treatment by the researcher.",{"count":140,"type":19},200,[22],"This study aims to systematically compare the clinical efficacy (venous closure rate and symptom relief rate), safety (perioperative and postoperative complications), and cost-effectiveness (direct medical costs) of domestic Xianruida radiofrequency catheter and imported Medtronic catheter in endovenous radiofrequency ablation for varicose veins through a single-center, prospective, non-inferiority randomized controlled trial.",[57,144,145],"Venous Insufficiency of Leg","Vascular Disease，Peripheral",[147,148,149],"varicose veins of the great saphenous veins","radiofrequency ablation","catheters","2025-06-29",{"date":152,"type":35},"2025-07-01",{"date":154,"type":19},"2025-08-01",{"date":156,"type":19},"2026-10-01",{"name":41,"class":42},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":167,"studyType":54,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100581430","effect-of-anticoagulant-and-antiplatelet-drug-intervention-on-postoperative-major-adverse-events-in-patients-with-padphase-ii-100581430","NCT06850207","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II","Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with Peripheral Arterial Disease：Phase II","Inclusion Criteria:\n\n* 1\\. History of PAD, or a history of intermittent claudication with an ankle\u002Fbrachial blood pressure ratio \\\u003C 0.9, or angiography-confirmed significant peripheral arterial stenosis (≥50%).\n\n  2\\. Underwent endovascular treatment for aortoiliac, femoral, popliteal, or infrapopliteal arteries.\n\n  3\\. No restrictions on endovascular treatment methods, including all internationally recognized devices and techniques used in real-world practice.\n\n  4\\. Agreed and signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. \\*\\*Patients with a history of stroke within the past month\\*\\* or a history of hemorrhagic or lacunar stroke.\n\n  2\\. Patients with a known ejection fraction \\\u003C 30% or severe heart failure with Class III\u002FIV symptoms.\n\n  3\\. Patients with non-cardiovascular diseases associated with poor prognosis(e.g., metastatic cancer) or interventions that increase the risk of adverse events in the study.\n\n  4\\. Patients with a history of allergies or known contraindications to drugs such as rivaroxaban or aspirin.\n\n  5\\. Patients with any known liver disease associated with coagulation disorders. 6. Pregnant or breastfeeding women, or women of childbearing potential who are sexually active and not using effective contraception.\n\n  7\\. Patients with known contraindications to any study-related procedures.",{"count":166,"type":19},6000,"12 Months","This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up by January 31, 2029). Patients will be grouped according to different combinations of anticoagulant and antiplatelet drugs used postoperatively for PAD. The types, dosages, and duration of postoperative anticoagulant and antiplatelet drug use will be recorded. Follow-up assessments will be conducted at 1 month, 6 months, and 12 months postoperatively to document the occurrence of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb Events (MALE) in the enrolled patients.",[170],"Peripheral Arterial Disease(PAD)",[172,173,174],"peripheral arterial disease","Anticoagulant and Antiplatelet Drug","Adverse Events","2025-02-23",{"date":177,"type":35},"2025-02-27",{"date":179,"type":19},"2025-02-28",{"date":181,"type":19},"2029-01-31",{"name":41,"class":42},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":20,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":91},"100570736","comparative-analysis-of-radiofrequency-ablation-and-microwave-ablation-procedures-for-the-treatment-of-small-saphenous-varicose-veins-100570736","NCT06711120","Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins","Randomized Controlled Study of Radio Frequency and Microwave of the Small Saphenous Vein","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years;\n* Clinical diagnosis of primary varicose veins of the lower extremities, CEAP clinical classification C2-C6, requiring treatment of the great and\u002For small saphenous vein segments, and at least 1 of the clinical symptoms of swelling, pain, burning sensation, heaviness, easy fatigue, itchy skin, and night cramps;\n* Valve insufficiency of the great saphenous vein, small saphenous vein, or transport vein;\n* Doppler ultrasound confirmation of a saphenous vein diameter greater than 3 mm and less than 12 mm in the standing position;\n* Only one limb per patient was selected for inclusion in the study;\n* Patients signed an informed consent form and were willing to co-operate in completing the protocol-specified investigations and follow-up visits.\n\nExclusion Criteria:\n\n* Thrombosis of the great saphenous or small saphenous vein, or combined deep vein thrombosis, or previous history of deep vein thrombosis or pulmonary embolism.\n* Recurrent varicose veins after previous treatment.\n* Severe distortion of the great saphenous vein with anticipated catheter failure.\n* Severe lower limb ischaemia (CLI) (ABPI \\\u003C0.8).\n* Known allergy to medications and device materials involved in the study.\n* Pre-existing implanted pacemaker, defibrillator, currently on regular anticoagulation therapy (e.g., warfarin, heparin).\n* Women who are pregnant or breastfeeding.\n* Unable or unwilling to complete the questionnaire.\n* Participating in a study of another drug or device.\n* Life expectancy \\\u003C1 year.\n* Those undergoing treatment for skin malignancies other than non-melanoma.\n* Daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain due to venous disease.\n* In the judgement of the investigator, endovenous therapy is not appropriate.","90 Years",{"count":18,"type":19},[22],"Objective: To investigate the clinical efficacy of ultrasound-guided radiofrequency ablation and microwave ablation in the treatment of primary saphenous varicose veins.",[57,144,145],[196,148,197],"varicose veins of the small saphenous veins","microwave ablation","2024-11-28",{"date":200,"type":35},"2024-12-02",{"date":202,"type":19},"2024-12-01",{"date":204,"type":19},"2025-12-01",{"name":41,"class":42},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":190,"enrollmentInfo":212,"targetDuration":214,"studyType":54,"phases":4,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":227,"locationsCount":91},"100569361","observation-of-pain-during-the-treatment-of-great-saphenous-vein-using-microwave-ablation-and-analysis-of-related-factors-100569361","NCT06693245","Observation of Pain During the Treatment of Great Saphenous Vein Using Microwave Ablation， and Analysis of Related Factors","Inclusion Criteria:\n\n1. Age≥ 18 years old, ≤ 90 years old;\n2. the patient's life expectancy is greater than 12 months;\n3. The clinical diagnosis is primary VVs, CEAP classification C2-C6, and the GSV segment needs to be treated, including pain, burning sensation, heaviness, fatigue, itchy skin, night cramps and other clinical symptoms;\n4. Doppler ultrasound confirmed that the diameter of GSV was greater than 3mm and less than 12mm when standing;\n5. Doppler ultrasound confirms that GSV is located in the saphenofascia or the distance between GSV and the skin surface is \\>1cm;\n6. endovenous microwave ablation treatment only for unilateral GSV walking area;\n7. The patient is willing to cooperate with the completion of the examination specified in the protocol.\n\nExclusion Criteria:\n\n1. GSV thrombosis, or combined with deep vein thrombosis, or previous history of deep vein thrombosis and pulmonary embolism;\n2. patients with recurrence after prior VVs-related surgery (C2r);\n3. the GSV trunk is severely distorted, and it is expected that the catheter will not be able to pass;\n4. Severe ischemia of the lower limbs, Ankle brachial pressure index (ABPI) \\\u003C 0.8;\n5. Known allergy to the drugs and device materials involved in the study;\n6. Previously implanted with a pacemaker or defibrillator, and currently receiving regular anticoagulation therapy (such as warfarin, heparin);\n7. Pregnant or lactating females;\n8. Patients who are unable or unwilling to participate in the study;\n9. Participating in the research of other drugs or devices;\n10. Skin malignancies other than non-melanoma that are being treated;\n11. daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain caused by venous disease;\n12. The investigator judged that endovenous treatment was not suitable;",{"count":213,"type":19},155,"1 Day","Objective: This study is a single-center prospective observational research that recorded patients' pain scores at four time points during surgery (puncture and catheter insertion, swelling fluid injection, microwave generator operation, and end of surgery). It analyzed the correlation between pain during microwave ablation treatment for great saphenous vein varicosities and factors such as age, gender, body mass index, volume of swelling fluid used, and others, in order to summarize and improve surgical details to reduce patients' intraoperative pain.",[145,144,57],[218,219,220,221],"Varicose veins of the lower extremities","Endovenous Microwave Ablation","intraoperative pain","visual analogue scale of pain","2024-11-15",{"date":224,"type":35},"2024-11-18",{"date":202,"type":19},{"date":204,"type":19},{"name":41,"class":42},""]